(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/028819 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 9/00* (2006.01)
A61K 31/495 (2006.01)

(21) International Application Number:
PCT/IB2023/057889

(22) International Filing Date:
04 August 2023 (04.08.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P2200312 05 August 2022 (05.08.2022) HU

(71) Applicant: **RICHTER GEDEON NYRT.** [HU/HU]; Gyömröi út 19-21., 1103 Budapest (HU).

(72) Inventors: **KONTA, Melinda**; Napfény u. 5., 1098 Budapest (HU). **SZAKONYI, Gergely**; Karcag utca 54. fsz. 8., 1116 Budapest (HU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV,

(54) Title: ORALLY DISINTEGRATING PHARMACEUTICAL TABLET CONTAINING CARIPRAZINE




Figure 1

(57) Abstract: An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt% of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt% of a disintegrant, between 0.1 and 5 wt% of colloidal silicon dioxide, between 0.1 and 10 wt% of a taste masking agent, between 0.1 and 5 wt% of a lubricant, and up to 100 wt% of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and/or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

WO 2024/028819 A1

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*